𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The French accelerator mass spectrometry facility ASTER: Improved performance and developments

✍ Scribed by Maurice Arnold; Silke Merchel; Didier L. Bourlès; Régis Braucher; Lucilla Benedetti; Robert C. Finkel; Georges Aumaître; Andreas Gottdang; Matthias Klein

Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
551 KB
Volume
268
Category
Article
ISSN
0168-583X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Investigating the use of an octupole ion
Investigating the use of an octupole ion guide for ion storage and high-pass mass filtering to improve the quantitative performance of electrospray ion trap mass spectrometry
✍ Robert D. Voyksner; Heewon Lee 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

An octupole radio frequency (rf) ion guide was evaluated for storage and filtering of ions generated by electrospray prior to introduction into an ion trap mass spectrometer. The control of the rf potential on the ion guide enabled its operation as a high-pass mass filter, removing low-mass chemical

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti